Literature DB >> 26248874

Olive Oil-derived Oleocanthal as Potent Inhibitor of Mammalian Target of Rapamycin: Biological Evaluation and Molecular Modeling Studies.

Mohammad A Khanfar1, Sanaa K Bardaweel1, Mohamed R Akl2, Khalid A El Sayed2.   

Abstract

The established anticancer and neuroprotective properties of oleocanthal combined with the reported role of mammalian target of rapamycin (mTOR) in cancer and Alzheimer's disease development encouraged us to examine the possibility that oleocanthal inhibits mTOR. To validate this hypothesis, we docked oleocanthal into the adenosine triphosphate binding pocket of a close mTOR protein homologue, namely, PI3K-γ. Apparently, oleocanthal shared nine out of ten critical binding interactions with a potent dual PIK3-γ/mTOR natural inhibitor. Subsequent experimental validation indicated that oleocanthal indeed inhibited the enzymatic activity of mTOR with an IC50 value of 708 nM. Oleocanthal inhibits the growth of several breast cancer cell lines at low micromolar concentration in a dose-dependent manner. Oleocanthal treatment caused a marked downregulation of phosphorylated mTOR in metastatic breast cancer cell line (MDA-MB-231). These results strongly indicate that mTOR inhibition is at least one of the factors of the reported anticancer and neuroprotective properties of oleocanthal.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  antiproliferative; breast cancer; docking; mTOR; oleocanthal

Mesh:

Substances:

Year:  2015        PMID: 26248874      PMCID: PMC5051273          DOI: 10.1002/ptr.5434

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  45 in total

Review 1.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

2.  Synthesis and assignment of absolute configuration of (-)-oleocanthal: a potent, naturally occurring non-steroidal anti-inflammatory and anti-oxidant agent derived from extra virgin olive oils.

Authors:  Amos B Smith; Qiang Han; Paul A S Breslin; Gary K Beauchamp
Journal:  Org Lett       Date:  2005-10-27       Impact factor: 6.005

3.  Chemical proteomics-driven discovery of oleocanthal as an Hsp90 inhibitor.

Authors:  Luigi Margarucci; Maria Chiara Monti; Chiara Cassiano; Matteo Mozzicafreddo; Mauro Angeletti; Raffaele Riccio; Alessandra Tosco; Agostino Casapullo
Journal:  Chem Commun (Camb)       Date:  2013-05-24       Impact factor: 6.222

4.  Pharmacophore modeling, homology modeling, and in silico screening reveal mammalian target of rapamycin inhibitory activities for sotalol, glyburide, metipranolol, sulfamethizole, glipizide, and pioglitazone.

Authors:  Mohammad A Khanfar; Majed M AbuKhader; Saja Alqtaishat; Mutasem O Taha
Journal:  J Mol Graph Model       Date:  2013-03-13       Impact factor: 2.518

5.  A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.

Authors:  A Sekulić; C C Hudson; J L Homme; P Yin; D M Otterness; L M Karnitz; R T Abraham
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

6.  Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase.

Authors:  Gary G Chiang; Robert T Abraham
Journal:  J Biol Chem       Date:  2005-05-16       Impact factor: 5.157

Review 7.  Mediterranean diet and cognitive decline.

Authors:  F Panza; V Solfrizzi; A M Colacicco; A D'Introno; C Capurso; F Torres; A Del Parigi; S Capurso; A Capurso
Journal:  Public Health Nutr       Date:  2004-10       Impact factor: 4.022

8.  Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199).

Authors:  A V Tinker; S Ellard; S Welch; F Moens; G Allo; M S Tsao; J Squire; D Tu; E A Eisenhauer; H MacKay
Journal:  Gynecol Oncol       Date:  2013-05-11       Impact factor: 5.482

9.  G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.

Authors:  Ning Gao; Daniel C Flynn; Zhuo Zhang; Xiao-Song Zhong; Valerie Walker; Ke Jian Liu; Xianglin Shi; Bing-Hua Jiang
Journal:  Am J Physiol Cell Physiol       Date:  2004-03-17       Impact factor: 4.249

10.  Olive phenolics as c-Met inhibitors: (-)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models.

Authors:  Mohamed R Akl; Nehad M Ayoub; Mohamed M Mohyeldin; Belnaser A Busnena; Ahmed I Foudah; Yong-Yu Liu; Khalid A Ei Sayed
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

View more
  16 in total

1.  The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment.

Authors:  Nehad M Ayoub; Abu Bakar Siddique; Hassan Y Ebrahim; Mohamed M Mohyeldin; Khalid A El Sayed
Journal:  Eur J Pharmacol       Date:  2017-06-15       Impact factor: 4.432

2.  Tissue Distribution of Oleocanthal and Its Metabolites after Oral Ingestion in Rats.

Authors:  Anallely López-Yerena; Anna Vallverdú-Queralt; Olga Jáuregui; Xavier Garcia-Sala; Rosa M Lamuela-Raventós; Elvira Escribano-Ferrer
Journal:  Antioxidants (Basel)       Date:  2021-04-27

Review 3.  The Biological Activities of Oleocanthal from a Molecular Perspective.

Authors:  Kok-Lun Pang; Kok-Yong Chin
Journal:  Nutrients       Date:  2018-05-06       Impact factor: 5.717

4.  (-)-Oleocanthal Prevents Breast Cancer Locoregional Recurrence After Primary Tumor Surgical Excision and Neoadjuvant Targeted Therapy in Orthotopic Nude Mouse Models.

Authors:  Abu Bakar Siddique; Nehad M Ayoub; Afsana Tajmim; Sharon A Meyer; Ronald A Hill; Khalid A El Sayed
Journal:  Cancers (Basel)       Date:  2019-05-08       Impact factor: 6.639

5.  Novel liquid-liquid extraction and self-emulsion methods for simplified isolation of extra-virgin olive oil phenolics with emphasis on (-)-oleocanthal and its oral anti-breast cancer activity.

Authors:  Abu Bakar Siddique; Hassan Ebrahim; Mohamed Mohyeldin; Mohammed Qusa; Yazan Batarseh; Ahmed Fayyad; Afsana Tajmim; Sami Nazzal; Amal Kaddoumi; Khalid El Sayed
Journal:  PLoS One       Date:  2019-04-09       Impact factor: 3.240

6.  Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells.

Authors:  Bruna Corominas-Faja; Elisabet Cuyàs; Jesús Lozano-Sánchez; Sílvia Cufí; Sara Verdura; Salvador Fernández-Arroyo; Isabel Borrás-Linares; Begoña Martin-Castillo; Ángel G Martin; Ruth Lupu; Alfons Nonell-Canals; Melchor Sanchez-Martinez; Vicente Micol; Jorge Joven; Antonio Segura-Carretero; Javier A Menendez
Journal:  Carcinogenesis       Date:  2018-04-05       Impact factor: 4.944

7.  (-)-Oleocanthal as a Dual c-MET-COX2 Inhibitor for the Control of Lung Cancer.

Authors:  Abu Bakar Siddique; Phillip C S R Kilgore; Afsana Tajmim; Sitanshu S Singh; Sharon A Meyer; Seetharama D Jois; Urska Cvek; Marjan Trutschl; Khalid A El Sayed
Journal:  Nutrients       Date:  2020-06-11       Impact factor: 5.717

Review 8.  Current Disease-Targets for Oleocanthal as Promising Natural Therapeutic Agent.

Authors:  Antonio Segura-Carretero; Jose Antonio Curiel
Journal:  Int J Mol Sci       Date:  2018-09-24       Impact factor: 5.923

Review 9.  Phenolic Compounds Isolated from Olive Oil as Nutraceutical Tools for the Prevention and Management of Cancer and Cardiovascular Diseases.

Authors:  Patricia Reboredo-Rodríguez; Alfonso Varela-López; Tamara Y Forbes-Hernández; Massimiliano Gasparrini; Sadia Afrin; Danila Cianciosi; Jiaojiao Zhang; Piera Pia Manna; Stefano Bompadre; José L Quiles; Maurizio Battino; Francesca Giampieri
Journal:  Int J Mol Sci       Date:  2018-08-06       Impact factor: 5.923

Review 10.  The Sources of Essential Fatty Acids for Allergic and Cancer Patients; a Connection with Insight into Mammalian Target of Rapamycin: A Narrative Review

Authors:  Zhila Arshad; Soheila Rezapour-Firouzi; Mahshid Mohammadian
Journal:  Asian Pac J Cancer Prev       Date:  2018-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.